stoxline Quote Chart Rank Option Currency Glossary
  
Acer Therapeutics Inc. (ACER)
0.6601  -0.144 (-17.95%)    11-20 15:59
Open: 0.7968
High: 0.85
Volume: 574,675
  
Pre. Close: 0.8045
Low: 0.6601
Market Cap: 16(M)
Technical analysis
2023-12-01 4:18:01 PM
Short term     
Mid term     
Targets 6-month :  0.93 1-year :  1.07
Resists First :  0.79 Second :  0.92
Pivot price 0.82
Supports First :  0.6 Second :  0.49
MAs MA(5) :  0.78 MA(20) :  0.83
MA(100) :  0.81 MA(250) :  1.28
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  49.4 D(3) :  60.4
RSI RSI(14): 30.1
52-week High :  4.55 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACER ] has closed below the lower bollinger band by 31.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ACER ] is to continue within current trading range. Bollinger Bands are 14% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.86 - 0.86 0.86 - 0.87
Low: 0.77 - 0.78 0.78 - 0.78
Close: 0.79 - 0.81 0.81 - 0.82
Company Description

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Headline News

Tue, 21 Nov 2023
Zevra Therapeutics completes Acer acquisition in $91m deal - Pharmaceutical Technology

Mon, 20 Nov 2023
Zevra Therapeutics Acquires Acer Therapeutics - Contract Pharma

Mon, 20 Nov 2023
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease ... - Yahoo Finance

Thu, 02 Nov 2023
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote ... - Yahoo Finance

Fri, 15 Sep 2023
Zevra adds Edsivo for vEDS to its rare disease portfolio in new... - Ehlers-Danlos News

Tue, 05 Sep 2023
Zevra Therapeutics to Acquire Acer Therapeutics - BioPharm International

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 24 (M)
Shares Float 18 (M)
Held by Insiders 13.7 (%)
Held by Institutions 29.9 (%)
Shares Short 494 (K)
Shares Short P.Month 898 (K)
Stock Financials
EPS -1.93
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.37
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -65.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.81
Qtrly Earnings Growth 0 %
Operating Cash Flow -32 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.35
PEG Ratio 0
Price to Book value -0.49
Price to Sales 0
Price to Cash Flow -0.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android